Ribociclib Nitroso Impurity 3

It an one of impurity present in Ribociclib, ribociclib is a selective cyclin-dependent kinase inhibitor that acts on the progression of cancer by inhibiting two proteins. Targeting CDK4/6 is ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib is a selective CDK4/6 inhibitor and has dose-dependent antitumor activity in several preclinical models. It inhibited the growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating, also used to treat HR+ and metastatic breast cancer.

Additional information

Catalogue No.

VE0010064

CAS No.

N/A

Molecular Formula

C23H29N9O2

Molecular Weight

463.5 g/mol

Status

In-stock

References

F. Byers, PharmD, BCOP, K. (2021). Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer. Journal of the Advanced Practitioner in Oncology, 12(1). https://doi.org/10.6004/jadpro.2021.12.1.8